Sex-mismatched red blood cell transfusions
BiologicalSex-mismatched red blood cell transfusions
NCT Number: NCT06840756
Red blood cell (RBC) transfusions are selected based upon matching donor and recipient blood group: donor and recipient sex are not considered when selecting blood for transfusion. Hence, transfused patients can currently receive sex-matched and/or unmatched RBCs when transfusions are given. Sex-matched stem cell transplants, and some solid organ transplants, have shown that sex-matching donor to recipient improves patient outcomes. Recent exploratory studies have also suggested that patient outcomes could be improved by sex-matching for RBC transfusion. There is emerging evidence of underlying biologic mechanism(s) to support these observations. This study is designed as a randomized controlled trial and will explore the impact on patients who receive RBC transfusions from donors of the same sex ("sex-matched") compared with donors of the opposite sex ("sex-mismatched").
The trial will study adult patients admitted to the Intensive Care Unit who require an RBC transfusion. Patients will be assigned (through a process called randomization) to receive sex-matched RBCs or sex-mismatched RBCs to determine if there is a difference in mortality between those receiving matched versus mismatched RBCs. The results of this trial could have direct implications on resources, blood inventory, and RBC transfusion ordering practices.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 4
Hamilton General Hospital, Hamilton, Ontario, Canada
Background: Red blood cell (RBC) transfusions are selected based upon donor and recipient blood group compatibility without consideration of donor and recipient sex. Stem cell transplants, and some solid organ transplants, have shown that sex-matching donor to recipient improves patient outcomes. The Principal Investigator has completed a systematic review/meta-analysis and a 40,000 patient exploratory analysis; both showed a signal of benefit from sex-matched RBC transfusion. Biological findings to support the hypothesis that sex-matched RBC transfusions improve survival in recipients are also emerging.
Controversial results have emerged from observational studies and a randomized controlled trial (RCT) regarding recipient mortality from sex-mismatched RBC transfusions; hence, equipoise exists.
The Principal Investigator completed a multisite pilot RCT that showed feasibility for conducting a large-scale RCT and has helped to inform design for this study proposal. The goal of this research project is to develop a precision transfusion strategy based on sex-matching of blood donor and recipient to minimize adverse effects and improve patient outcomes post-transfusion.
Overall Research Question: In transfused adult patients admitted to the Intensive Care Unit (ICU), do donor-recipient sex-matched RBC transfusions result in improved mortality compared to sex-mismatched RBC transfusions?
Methods: This study is a superiority RCT with pragmatic features that will occur across participating sites in Canada.
Study population: adult patients (age≥18) who are hospitalized with admission to an eligible ICU and requiring RBC transfusion.
Intervention: donor-recipient sex-matched RBC transfusions. Comparison: donor-recipient sex-mismatched RBC transfusions.
Primary Outcome: 30 day mortality from time of randomization. Secondary Outcomes: time to death, 30 day in-hospital mortality, 90 day mortality, hemoglobin and creatinine increment, ICU and hospital lengths of stay, number/type of transfused products and cost effectiveness analysis. Subgroup analyses will consider recipient sex, age, transfusion exposure, blood type, admitting diagnosis, baseline hemoglobin/creatinine.
Expertise: The study team is uniquely positioned with extensive knowledge and expertise in transfusion medicine, research methodology, conduct of large pragmatic trials, and biostatistics. The study team will collaborate with Canadian Blood Services and experts in blood utilization, and operational modeling. This study is supported and endorsed by the Canadian Transfusion Trials Group.
Importance & Outcomes: Anemia is common in critically ill patients; as many as 90% of patients will become anemic by the third day of their ICU admission. Between 20% and 40% of critically ill patients admitted to the ICU will require RBC transfusion; each patient will receive on average 2 to 5 RBC units. The Age of Blood Evaluation (ABLE) study showed a 90 day all cause mortality rate of 35-37% in the transfused ICU population studied. The pilot study reflected similar mortality rates. If providing sex-matched transfusions can decrease mortality, this could translate to high numbers of preventable deaths given that 85 million RBC units are transfused globally each year. If this study finds that donor-recipient sex-matching saves lives, this would require changes at the level of the blood supplier to identify sex on each RBC unit, and changes at the hospital level that would incorporate sex-matching into the selection of compatible blood for each patient.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sex-mismatched red blood cell transfusions
Sex-matched red blood cell transfusions
Time frame: From randomization to 30 days post-randomization.
Death within 30 days of randomization.
Time frame: From randomization to 30 days post-randomization.
In-hospital death within 30 days of randomization.
Time frame: From randomization to 90 days post-randomization.
Death within 90 days of randomization.
Time frame: From randomization to 30 days post-randomization.
Time to in-hospital death within 30 days of randomization.
Time frame: From time of randomization until death or discharge from ICU; up to 90 days post randomization.
Lowest hemoglobin post-randomization during ICU admission.
Time frame: From time of randomization during ICU admission, until death or discharge from ICU; up to 90 days post randomization.
Need for renal replacement therapy e.g. CRRT or HD post randomization during ICU admission.
Time frame: From randomization to 30 days post-randomization.
The number of ICU-free days over 30 days and the number of days in hospital over 30 days.
Time frame: From randomization to 90 days post-randomization.
Total number of transfusion interventions, cumulative proportion of units received that were from a sex-mismatched donor
Time frame: From randomization to 30 days post-randomization.
Reactions related to RBC transfusions.
Time frame: From randomization to 90 days post-randomization.
Cost effectiveness measured using the incremental cost per life year saved (ICER) between sex-matched and mismatched transfusions.
Contact information is provided by the study sponsor or research team.
Bambie Levoy-Jones, Honours Bachelor of Science
CONTACT
1-905-525-9140 ext. 24928
Michelle Zeller, Doctor of Medicine
CONTACT
1-905-525-9140 ext. 73928
Michelle Zeller
Other
Effects of Donor-recipient Sex-matched Versus Sex-mismatched Red Blood Cell Transfusion on Outcomes in Critically Ill Adult Patients
Acronym: SexMATTERS RCT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02835937
Ambulatory Care, Anemia
Scottsdale, Arizona, United States
View Trial DetailsNCT07108374
Red Blood Cell Transfusions
Palo Alto, California, United States
View Trial DetailsNCT07732114
Critically Ill Intensive Care Unit Patients
Alexandria, Shebin El-Kom, Egypt
View Trial DetailsNCT07491172
Cardiovascular, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Hialeah, Florida, United States
View Trial Details